SLC5A2 and type 2 diabetes mellitus: In exploratory analyses from two large outcome trials, a hypothesis that SGLT-2 inhibition with empagliflozin or canagliflozin has the potential to reduce the risk of kidney disease progression in people with T2DM was raised.